Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity (Q34023081)

30 July 2017

Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity (English)

1 reference

30 July 2017

anti-retroviral agent

0 references

author name string

Moyle G

series ordinal

1

1 reference

30 July 2017

1 August 2000

1 reference

30 July 2017

Clinical Therapeutics

1 reference

30 July 2017

22

1 reference

30 July 2017

911-36; discussion 898

1 reference

30 July 2017

8

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

A risk-benefit assessment of HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Mitochondrial toxicity of antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Inhibition of HIV reverse transcriptase by 2',3'-dideoxynucleoside triphosphates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

The intracellular phosphorylation of (-)-2'-deoxy-3'-thiacytidine (3TC) and the incorporation of 3TC 5'-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Lack of mitochondrial toxicity in CEM cells treated with carbovir

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Treatment of mitochondrial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Neonatal Fanconi syndrome due to deficiency of complex III of the respiratory chain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Mitochondrial respiratory chain disorders and the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Neuropathology and pathogenesis of mitochondrial diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Mitochondrial DNA polymerase gamma deficiency and mtDNA depletion in a child with Alpers' syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Progressive poliodystrophy (Alpers' disease) with a defect in cytochrome aa3 in muscle: a report of two unrelated patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Does hepatitis C cause liver injury by pathways associated with mitochondrial dysfunction?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Hydroxyurea and HIV: 5 years later--from antiviral to immune-modulating effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Hydroxyurea toxicity in human immunodeficiency virus-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Hydroxyurea-induced neurotoxicity in HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Protective effect of P. fraternus against ethanol-induced mitochondrial dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

The didanosine Expanded Access Program: safety analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

The pc12 cell as a model for studies of the mechanism of induction of peripheral neuropathy by anti-HIV-1 dideoxynucleoside analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Neuroprotective activity of acetyl-L-carnitine: studies in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Nerve growth factor binding in aged rat central nervous system: effect of acetyl-L-carnitine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Mitochondrial myopathy caused by long-term zidovudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Dilated cardiomyopathy in a zidovudine-treated AIDS patient

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Lack of muscle toxicity with didanosine (ddI). Clinical and experimental studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

AZT decreases rat myocardial cytochrome oxidase activity and increases beta-myosin heavy chain content

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Mitochondrial myopathy caused by long-term zidovudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Mitochondrial abnormalities in human immunodeficiency virus-associated myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Molecular mechanism of the short-term cardiotoxicity caused by 2',3'-dideoxycytidine (ddC): modulation of reactive oxygen species levels and ADP-ribosylation reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Mitochondrial sensitivity to AZT.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Prognosis in AZT myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Riboflavin to treat nucleoside analogue-induced lactic acidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Riboflavine and severe lactic acidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Protease inhibitor-associated hyperinsulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Lipodystrophy in patients naive to HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Lipodystrophy associated with nevirapine-containing antiretroviral therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Metabolic abnormalities and use of HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Fat accumulation and HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

The formation of respiratory chain complexes in mitochondria is under the proteolytic control of the m-AAA protease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Acute HIV infection among patients tested for mononucleosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

"Buffalo hump" in men with HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Benign symmetric lipomatosis associated with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

"Buffalo hump" in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Mitochondrial dysfunction in multiple symmetrical lipomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Multiple symmetric lipomatosis: abnormalities in complex IV and multiple deletions in mitochondrial DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Defects of mitochondrial respiratory chain in multiple symmetric lipomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Clinical features associated with the A-->G transition at nucleotide 8344 of mtDNA ("MERRF mutation").

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

A gene for congenital generalized lipodystrophy maps to human chromosome 9q34.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

PPAR gamma is required for placental, cardiac, and adipose tissue development

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980064-8

7 January 2021

10.1016/S0149-2918(00)80064-8

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10972629